Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Genomictree, Inc. (228760) Stock Price & Analysis

228760 Stock Chart & Stats

₩9,970.00₩70.00(0.71%)
At close: 3:30 PM GMT+9
KRW 10,000KRW 12,500KRW 15,0003 Aug18 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
KRW 9,590.00 - KRW 10,010.00
52-Week Range
KRW 8,790.00 - KRW 33,300.00
Previous Close
KRW 9,900.00
Volume
N/A
Average Volume (3M)
90.83K
Market Cap
KRW 244.26B
Enterprise Value
KRW 187.37B
Total Cash (Recent Filing)
KRW 75.39B
Total Debt (Recent Filing)
KRW 55.19M
Price to Earnings (P/E)
―
Beta
0.10
Next Earnings
Nov 06, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

The very low debt burden reduces refinancing pressure and preserves financial flexibility while Genomictree funds research and development. A sizable equity base provides a meaningful cushion against operating volatility, supporting the company’s ability to pursue its diagnostic strategy without heavy reliance on lenders.

Gross-margin Recovery

The return to a slightly positive gross margin indicates some improvement in the economics of the company’s offerings, even though it has not yet reached profitability. If sustained, better product-level economics could provide a foundation for operating leverage as diagnostic commercialization develops.

Specialized Diagnostics Platform

Genomictree operates in a specialized molecular-diagnostics niche centered on genomic and DNA-methylation biomarkers. Its combination of assays, test kits, and clinical decision-support applications gives the business a focused platform that can support multiple diagnostic uses over time.

Bears Say

Persistent Operating Losses

Persistent operating and net losses show that the current revenue base is not covering the company’s cost structure. Continued losses can consume equity over time, constrain reinvestment, and make durable profitability dependent on substantial improvement in commercialization or operating efficiency.

Ongoing Cash Burn

Negative operating and free cash flow means the business is not currently funding itself internally. Continued cash consumption increases reliance on existing reserves or external financing, potentially limiting strategic flexibility and making the pace of investment harder to sustain.

Volatile Declining Revenue

The post-2022 revenue contraction and only modest 2025 rebound point to an inconsistent commercial trajectory. Unstable top-line performance makes fixed-cost absorption more difficult, delays operating leverage, and reduces confidence that recent margin improvement can persist.

Genomictree, Inc. News

228760 FAQ

What was Genomictree, Inc.’s price range in the past 12 months?
Genomictree, Inc. lowest stock price was ₩8790.00 and its highest was ₩33300.00 in the past 12 months.
What is Genomictree, Inc.’s market cap?
Genomictree, Inc.’s market cap is ₩244.26B.
When is Genomictree, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Genomictree, Inc.’s earnings last quarter?
Genomictree, Inc. released its earnings results on Aug 07, 2026. The company reported -₩100.585 earnings per share for the quarter.
Is Genomictree, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Genomictree, Inc. pay dividends?
Genomictree, Inc. does not currently pay dividends.
What is Genomictree, Inc.’s EPS estimate?
Genomictree, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genomictree, Inc. have?
Genomictree, Inc. has 24,859,201 shares outstanding.
What happened to Genomictree, Inc.’s price movement after its last earnings report?
Genomictree, Inc. reported an EPS of -₩100.585 in its last earnings report. Following the earnings report the stock price went down -2.458%.
Which hedge fund is a major shareholder of Genomictree, Inc.?
Currently, no hedge funds are holding shares in KR:228760
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology